-+ 0.00%
-+ 0.00%
-+ 0.00%

Dongcheng Pharmaceutical announced that its wholly-owned subsidiary Andike's technetium [99mTc] tetraline injection was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. This product is for diagnostic use only and can be used for myocardial perfusion imaging under drug load and at rest. The product is a Class B injection and is classified as a radiopharmaceutical for the diagnosis of the cardiovascular system. The “Medical Insurance Catalogue” will be implemented on January 1, 2026, and will not have a significant impact on the company's business performance for the time being.

Zhitongcaijing·12/07/2025 08:25:03
Listen to the news
Dongcheng Pharmaceutical announced that its wholly-owned subsidiary Andike's technetium [99mTc] tetraline injection was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. This product is for diagnostic use only and can be used for myocardial perfusion imaging under drug load and at rest. The product is a Class B injection and is classified as a radiopharmaceutical for the diagnosis of the cardiovascular system. The “Medical Insurance Catalogue” will be implemented on January 1, 2026, and will not have a significant impact on the company's business performance for the time being.